Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | — | — | — | 1 |
Lung neoplasms | D008175 | — | C34.90 | — | 1 | — | — | — | 1 |
Genetic therapy | D015316 | — | — | — | 1 | — | — | — | 1 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | — | 1 | — | — | — | 1 |
Carcinoma | D002277 | — | C80.0 | — | 1 | — | — | — | 1 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 1 | — | — | — | 1 |
Adenocarcinoma | D000230 | — | — | — | 1 | — | — | — | 1 |
Cholangiocarcinoma | D018281 | — | C22.1 | — | 1 | — | — | — | 1 |
Drug common name | Entinostat |
INN | entinostat |
Description | Entinostat is a member of the class of benzamides resulting from the formal condensation of the carboxy group of the pyridin-3-ylmethyl carbamate derivative of p-(aminomethyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an inhibitor of histone deacetylase isoform 1 (HDAC1) and isoform 3 (HDAC3). It has a role as an EC 3.5.1.98 (histone deacetylase) inhibitor, an antineoplastic agent and an apoptosis inducer. It is a member of pyridines, a carbamate ester, a substituted aniline, a primary amino compound and a member of benzamides. It is functionally related to a 1,2-phenylenediamine. |
Classification | Small molecule |
Drug class | enzyme inhibitors: histone deacetylase inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1 |
PDB | — |
CAS-ID | 209783-80-2 |
RxCUI | — |
ChEMBL ID | CHEMBL27759 |
ChEBI ID | — |
PubChem CID | 4261 |
DrugBank | — |
UNII ID | 1ZNY4FKK9H (ChemIDplus, GSRS) |